Skip to main content
Premium Trial:

Request an Annual Quote

LivFul, Global Access Diagnostics Partner to Offer SARS-CoV-2 Antigen Testing

NEW YORK — LivFul and Global Access Diagnostics said on Wednesday that they have partnered to offer a SARS-CoV-2 rapid antigen test in low- and middle-income countries.

The companies said they will offer a rapid SARS-CoV-2 antigen test developed by Mologic at an affordable price in these nations. Mologic partnered with UK-based GAD in late 2020 to make the test available in low- and middle-income countries at the cost of production.

"GAD's mission is to work in partnership with governments, donor organizations, regional experts, and the private sector to innovate in the technology and delivery of testing," Mark Radford, executive director of GAD, said in a statement.

"LivFul was founded to expand health access with products … [and] GAD takes a similar view as to how to ensure that people have access to quality, affordable health products," LivFul CEO Michael Norman added in the statement. "Their COVID-19 antigen test is being offered at the best price point of any similarly validated product."

The companies said they intend to expand their collaboration to include other diagnostics later. Alpharetta, Georgia-based LivFul currently offers two other SARS-CoV-2 tests — one that detects antibodies and one that detects viral nucleic acid — as well as insect repellent and personal protective equipment.